NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Diagnostics Advisory Committee (DAC) meeting minutes

**Minutes:** Confirmed

**Date and time:** 23 February 2022

**Location:** Via Zoom

## Attendees

Committee members present

1. Mark Kroese (Chair) Present for all items
2. Keith Abrams Present for all items
3. Liz Adair Present for all items
4. Rebecca Allcock Present for items 1 – 2.3.3
5. John Cairns Present for all items
6. Sam Creavin Present for all items
7. Neil Hawkins Present for all items
8. Michael Messenger Present for items 1 – 2.3.3
9. Karen Sennett Present for all items
10. Brian Shine Present for all items
11. Matt Stevenson Present for all items

NICE staff present

Sarah Byron, Programme Director Present for items 3 – 3.4.2

Rebecca Albrow, Associate Director Present for all items

Thomas Walker, Health Technology Assessment Adviser Present for items 1 – 2.3.3

Amy Crossley Health Technology Assessment Adviser Present for items 3 – 3.4.2

Simon Webster, Health Technology Assessment Analyst Present for items 1 – 2.3.3

Suvi Harmala, Health Technology Assessment Analyst Present for items 3 – 3.4.2

Donna Barnes, Project Manager Present for all items

Alex Sexton, Administrator Present for all items

Decision Support Unit representatives present

Allan Wailoo, Professor of Health Economics, Present for items 1 to 2.2.7
Director of NICE Decision Support Unit (DSU)

Ben Kearns, Research Fellow, DSU Present for items 1 to 2.2.7

External assessment group representatives present

Keith Cooper, Senior Research Fellow, Southampton Present for items 1 to 2.2.7

Health Technology Assessment Centre (SHTAC)

Jonathan Shepherd, Principal Research Fellow, SHTAC Present for items 1 to 2.2.7

Ines Souto Ribeiro, Senior Research Assistant, SHTAC Present for items 1 to 2.2.7

Marie Westwood, Reviews Manager, Kleijnen Present for items 3 to 3.3.6
Systematic Reviews Ltd (KSR)

Bram Ramaekers, Senior Health Economist, KSR Present for items 3 to 3.3.6

Specialist Committee Members present

Joanna Girling, Consultant Obstetric Medicine, Present for items 1 – 2.3.3
West Middlesex University Hospital and Chelsea &
Westminster Hospital NHS Foundation Trust

Sarah Findlay, Lay specialist committee member Present for items 1 – 2.3.3
Shonagh Haslam, Principal Clinical Biochemist, Present for items 1 – 2.3.3
Lancashire Teaching Hospitals

Jenny Myers, Consultant Obstetrician / Professor of Present for items 1 – 2.3.3
Obstetrics & Maternal Medicine, University of Manchester

Elaine Sheehan, Specialist Midwife for Hypertension Present for items 1 – 2.3.3
and Maternal Medicine, St. George’s University Hospitals
NHS Foundation Trust

Nigel Simpson, Senior Lecturer/Consultant in Present for items 1 – 2.3.3
Obstetrics & Gynaecology, University of Leeds
/ Leeds Teaching Hospitals Trust

Manu Vatish, Professor of Obstetrics, University of Oxford Present for items 1 – 2.3.3

Sotirios Bisdas, Consultant Neuroradiologist, Present for items 3 – 3.4.2
University College London Hospitals NHS Trust,
and Associate Professor of Neuroradiology,
Queen Square Institute of Neurology, UCL

Margaret Cheng, Lay specialist committee member Present for items 3 – 3.4.2

Tim England, Clinical Associate Professor / Present for items 3 – 3.4.2
Honorary Stroke Physician, University of Nottingham
and University Hospitals of Derby and Burton

Carole Gavin, Consultant in Emergency Medicine, Present for items 3 – 3.4.2
Salford Royal NHS Foundation Trust

Nigel Hoggard, Professor of Neuroradiology/ Present for items 3 – 3.4.2
Honorary Consultant Neuroradiologist,
University of Sheffield/Sheffield Teaching Hospitals
NHS Foundation Trust

Grant Mair, Senior Clinical Lecturer and Honorary Present for items 3 – 3.4.2
Consultant Neuroradiologist, University of Edinburgh

Kiruba Nagaratnam, Consultant Stroke Physician, Present for items 3 – 3.4.2
Royal Berkshire NHS Foundation Trust

Jonathan Shapey, Senior Clinical Lecturer and Present for items 3 – 3.4.2
Honorary Consultant Neurosurgeon, King's College
London/King's College Hospital

Li Su, Chair of Neuroimaging, University of Sheffield Present for items 3 – 3.4.2

and Senior Research Fellow, University of Cambridge

David Werring, Professor of Clinical Neurology, Present for items 3 – 3.4.2
UCL Queen Square Institute of Neurology

Observers present

Anastasia Chalkidou, Associate Director, MTEP/IP, NICE Present for items 3 – 3.4.2

Tara Chernick, Health Technology Adoption Present for items 3 – 3.4.2
Manager, NICE

Lyn Davies, Coordinator, NICE Present for items 1 – 2.2.7 and 3 – 3.3.6

Hayley Jones, Senior Lecturer, University of Bristol Present for items 1 – 2.2.7 and 3 – 3.3.6

Lynne Kincaid, Data and Analytics Team, NICE Present for items 3 - 3.3.6

Laura Marsden, Public Involvement Adviser, NICE Present for all items

Edgar Masanga, Business Analyst, NICE Present for items 3 – 3.4.2

Ian Mather, Business Analyst, NICE Present for items 1 – 2.3.3

Hosein Shabaninejad, Research Associate, Present for items 1 – 2.2.7 and 3 Newcastle University – 3.3.6

Heather Stephens, Senior Medical Technology Implementation Present for items 1 – 2.2.7
Manager, NICE

Louise Tanner, Research Associate, Newcastle University Present for items 1 – 2.2.7 and 3 – 3.3.6

## Minutes

### Evaluation of PlGF-based testing to help diagnose suspected pre-eclampsia (update of DG23)

### The Chair welcomed members of the committee and other attendees present to the meeting

The Chair noted apologies from standing committee members Diane Davies, Jim Gray, Shelley Rahman Haley, Patrick McGinley, Brendan Meyer, Alexandria Moseley and Alasdair Taylor.

* 1. The committee approved the minutes of the committee meeting held on 19 January 2022
	2. Part 1 – Open session
		1. The Chair welcomed representatives from NICE Decision Support Unit, external assessment group (EAG) representatives, members of the public, and company representatives from Perkin Elmer Health Sciences Limited, Quidel, Roche Diagnostics Limited and Thermo Fisher Scientific.
		2. The Chair asked all committee members to declare any new relevant interests in relation to the item being considered. The following standing committee members had notified these interests in advance of the meeting:

 Keith Abrams declared a financial interest as since May 2019 he has been a Partner and Director at Visible Analytics Limited, an HTA Consultancy, but has not been involved in any projects which involve a diagnostic technology. Via Visible Analytics he has advised Roche (Global, Basel) as regards a therapy (not diagnostics at all) for Spinal Muscular Atrophy (SMA). Since October 2017 he has received funding to support a MRC Industrial PhD Studentship from Swiss Precision Diagnostics/Clearblue for a project on prediction of early miscarriage. From July 2020 to date he is the COI on UKRI-NIHR-funded UK-REACH study looking at effect of ethnicity on morbidity and mortality due to COVID in UK health care workers. From July 2020 to December 2020 he was COI: Leicester Life Sciences Accelerator - Evaluating feasibility of workplace testing using Elephant Kiosk in SMEs. From March 2020 to date he has been the COI for various HDR UK supported studies on diagnosis and prognosis of COVID-19 in UK. From March 2020 to December 2020 he was a Member of the Leicester COVID-19 Taskforce. From March 2020 to July 2021 he was a Member of the HDR-UKRI-SAGE COVID-19 Taskforce. It was agreed that these interests would not prevent Keith Abrams from participating in the meeting.

Liz Adair declared an indirect interest in that she is the Quality Director of Viapath Group LLP. All the manufactures involved in this assessment supply Viapath Services LLP with laboratory supplies and equipment. It was agreed that this interest would not prevent Liz Adair from participating in the meeting.

John Cairns declared financial interests as he had advised Astellas on health economic modelling for roxadustat (interest ceased May 2021). It was agreed that this interest would not prevent John Cairns from participating in the meeting.

Sam Creavin declared a financial interest as he is a GP partner in an NHS practice. It was agreed that this interest would not prevent Sam Creavin from participating in the meeting.

Neil Hawkins declared a financial interest in that he has personally received fees for consultancy services provided to the Pharmaceutical Division of Roche AG. No services were provided to the Diagnostics Division. The consultancy services provided were unrelated to the technologies being considered for PlGF. It was agreed that this interest would not prevent Neil Hawkins from participating in the meeting.

Patrick McGinley declared a financial interest as he is a Faculty Member of MTech Access, advising on NHS finance flows, and receives an honorarium for this. He also declared non-financial personal and professional interests as he is a Strategic Council member of the All-Party Parliamentary Group (APPG) on Obesity, the Honorary Treasurer for the Association for Study of Obesity (ASO), and a Member of Obesity Policy Engagement Network UK (OPEN UK). It was agreed that these interests would not prevent Patrick McGinley from participating in the meeting.

Mike Messenger declared non-financial personal and professional interests as he was a collaborator on two oncology research programmes funded in kind by Roche Diagnostics between 2017-2020. The projects were IDX-LUNG integrated diagnostics for lung cancer screening, and a project to developing a machine learning based blood test for cancer. For both, he was co-investigator and Roche provided an in-kind contribution of biochemistry reagents. It was agreed that these interests would not prevent Mike Messenger from participating in the meeting.

Matt Stevenson declared an indirect interest in that he is part of a research team that has received funding from Roche Diagnostics via the University of Sheffield to explore the impact of biomarkers in patients with head trauma. The interest arose early 2021 and the project is ongoing. In the meeting he further declared that he is a member of the NICE Decision Support Unit but had no involvement with the work they have undertaken for this assessment. It was agreed that these interests would not prevent Matt Stevenson from participating in the meeting.

During the meeting, Brian Shine declared a non-financial professional and personal interest as members of his department at Oxford University Hospitals NHS Foundation Trust have run specimens and have received free reagents from Roche and Perkin Elmer. He has not been involved in any of the studies they have undertaken, and has not benefited personally. It was agreed that this interest would not prevent Brian Shine from participating in the meeting.

The following specialist committee members had notified these interests in advance of the meeting:

Sarah Findlay declared a financial interest as she is a medical publisher, the founder/CEO of Cedilla Publishing, and Section Editor for Women’s & Sexual Health at the BMJ Group. She also declared non-financial personal and professional interests as from 2018-19 she was the lay member/co-author of the NICE hypertensive disorders of pregnancy guideline, and the lay member of the James Lind Alliance Priority Setting Partnership on hypertensive disorders of pregnancy. Since 2019 she has been the lay member of the Trial Steering Committee (TSC) for the PARROT-2 study. It was agreed that these interests would not prevent Sarah Findlay from participating in the meeting.

Joanna Girling declared a financial interest, as until 2018 she undertook private practice (not more than 10 patients annually, payment for services provided from Insurance company or ‘self pay’). She also declared non-financial personal and professional interests as she is the author and co-author of publications about placental growth factor published in peer-reviewed medical journals. Since 2020 she has been the Principal Investigator at her NHS Trust for CRN portfolio study, “Placental growth factor repeat sampling for reduction of adverse perinatal outcomes in suspected pre-eclampsia (PARROT-2)”. She is part of a network of experts available to give clinical consultations for women affected by pre eclampsia for APEC “Action on Pre eclampsia“ charity. In February 2021 she was asked to attend a meeting with Quidel (suppliers of PLGF to her hospital) to discuss with them the business plan and other arrangements for continuing to get PLGF into their unit. She also declared indirect interests as she is a close relative of the Chief Investigator of the PARROT study and co-Chief Investigator of the PARROT-2 study, peer reviewed, non- commercial CRN portfolio trials researching clinical applications of placental growth factor. It was agreed that these interests would not prevent Joanna Girling from participating in the meeting.

Shonagh Haslam declared non-financial personal and professional interests as she is a member of the Association for Clinical Biochemistry (ACB) Scientific Committee. Her employer, Lancashire Teaching Hospitals (LTH), participated in the REMIT2 trial in 2018, and LTH will be participating in the PARROT2 trial. She presented for Roche Diagnostics at a UK meeting on pre-eclampsia markers in March 2021; no payment or hospitality were received. She presented for Roche Diagnostics at a Middle East meeting on SARS-CoV-2 antibody testing in November 2020; no payment or hospitality were received. It was agreed that these interests would not prevent Shonagh Haslam from participating in the meeting.

Jenny Myers declared a non-financial personal and professional interests as from March 2020 – March 2021 she was the NHS England Clinical Champion for implementation of AAC/ITP PlGF-based testing for pre-eclampsia. It was agreed that this interest would not prevent Jenny Myers from participating in the meeting.

Nigel Simpson declared a non-financial personal and professional interests as over the past four years he was part of the study group which evaluated PlGF in the HTA-funded PARROT trial. He also declared indirect interests as he occasionally speaks (for free) at educational meetings run by Action on Pre-eclampsia. It was agreed that these interests would not prevent Nigel Simpson from participating in the meeting.

Manu Vatish declared non-financial personal and professional interests as he is a Senior Clinical Academic at the University of Oxford, and has publications in this area:

* Predictive Performance of PlGF (Placental Growth Factor) for Screening Preeclampsia in Asymptomatic Women: A Systematic Review and Meta-Analysis Hypertension 2019 74 (5):1124.
* Angiogenic factors: potential to change clinical practice in pre-eclampsia? BJOG 2018.
* Diagnostic utility of angiogenic biomarkers in pregnant women with suspected preeclampsia: A health economics review Pregnancy Hypertension 2019
* Temporal and external validation of the fullPIERS model for the prediction of adverse maternal outcomes in women with pre-eclampsia Pregnancy Hypertension 2019
* Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio and Time to Delivery in Women With Suspected Preeclampsia Obstet Gynecol 2016
* Placental Growth Factor as a Prognostic Tool in Women With Hypertensive Disorders of Pregnancy: A Systematic Review Hypertension 2017
* Implementation of the sFlt-1/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practice Ultrasound Obstet Gynecol 2015
* Meta-Analysis and Systematic Review to Assess the Role of Soluble FMS-Like Tyrosine Kinase-1 and Placenta Growth Factor Ratio in Prediction of Preeclampsia: The SaPPPhirE Study – Hypertension 2018
* Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia – New England Journal of Medicine 2016
* Randomized Interventional Study on Prediction of Preeclampsia/Eclampsia in Women With Suspected Preeclampsia: INSPIRE – Hypertension 2019

 He further declared that the Biochemistry Department at Oxford undertook an analytic assessment of Perkin Elmer’s s Flt1/PlGF test. This did not involve him. In order to understand the granularity of their data , they approached him to perform a notes audit. This is ongoing and funded as a grant between the University of Oxford and Perkin Elmer. It was agreed that these interests would not prevent Manu Vatish from participating in the meeting.

* + 1. The Committee proceeded to discuss the Decision Support Unit report on ‘PlGF-based testing to help diagnose suspected pre-eclampsia (update of DG23)’
		2. The Committee was asked if there were any specific equality issues to consider in relation to this assessment.
		3. The Chair asked the representatives of the manufacturers whether they wished to comment on any matters of factual accuracy.
		4. The Chair thanked the manufacturer representatives, the DSU, EAG, and public observers for their attendance at the meeting.
		5. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
	1. Part 2 - Closed session
		1. The committee discussed confidential information submitted for this item.
		2. The committee then agreed on the content of the Diagnostics Consultation Document (DCD). The committee decision was reached by consensus.
		3. The committee asked the NICE technical team to prepare the DCD in line with their decisions.

### Evaluation of ‘Software with artificial intelligence derived algorithms for analysing CT brain scans in people with a suspected acute stroke’

* 1. The Chair welcomed members of the committee and other attendees present to the meeting.
	2. The Chair noted apologies from standing committee members Diane Davies, Jim Gray, Shelley Rahman Haley, Patrick McGinley, Michael Messenger, Brendan Meyer, Alexandria Moseley and Alasdair Taylor. He noted that Rebecca Allcock was not attending due to a conflict of interest.
	3. Part 1 – Open session
		1. The Chair welcomed external assessment group representatives, members of the public, and company representatives from Aidoc Medical Ltd, Avicenna.ai, Brainomix, icometrix, Ischemaview Inc and Viz.ai, Inc.
		2. The Chair asked all committee members to declare any new relevant interests in relation to the item being considered. The following standing committee members had notified these interests in advance of the meeting:

Keith Abrams declared a financial interest as since May 2019 he has been a Partner and Director at Visible Analytics Limited, an HTA Consultancy, but has not been involved in any projects which involve a diagnostic technology. Since October 2017 he has received funding to support a MRC Industrial PhD Studentship from Swiss Precision Diagnostics/Clearblue for a project on prediction of early miscarriage. From July 2020 to date he is the COI on UKRI-NIHR-funded UK-REACH study looking at effect of ethnicity on morbidity and mortality due to COVID in UK health care workers. From July 2020 to December 2020 he was COI: Leicester Life Sciences Accelerator - Evaluating feasibility of workplace testing using Elephant Kiosk in SMEs. From March 2020 to date he has been the COI for various HDR UK supported studies on diagnosis and prognosis of COVID-19 in UK. From March 2020 to December 2020 he was a Member of the Leicester COVID-19 Taskforce. From March 2020 to July 2021 he was a Member of the HDR-UKRI-SAGE COVID-19 Taskforce. It was agreed that these interests would not prevent Keith Abrams from participating in the meeting.

Liz Adair declared non-financial personal and professional interests as she is a Trustee at Carers Network, a charity which supports unpaid carers. She also declared an indirect interest as she is the Quality Director at Viapath Group LLP which is a medical laboratory pathology provider. GE Healthcare supply products for Viapath Services LLP. It was agreed that these interests would not prevent Liz Adair from participating in the meeting.

Rebecca Allcock had declared an indirect interest as her husband is employed by GE Healthcare, as the UKI Public Private Partnerships Service Manager, but has no direct involvement in any projects that cover AI software development for CT scanning. It was agreed that this interest precluded Rebecca Allcock from taking part in the discussion and she did not attend the meeting.

John Cairns declared financial interests as he had advised Astellas on health economic modelling for roxadustat (interest ceased May 2021) and Takeda on the economic evaluation of maribavir (interest ceased August 2021). He had also participated in a double-blinded focus group organized by PwC Switzerland on an epilepsy treatment (interest ceased December 2021). It was agreed that these interests would not prevent John Cairns from participating in the meeting.

Patrick McGinley declared a financial interest as he is a Faculty Member of MTech Access, advising on NHS finance flows, and receives an honorarium for this. He also declared non-financial personal and professional interests as he is a Strategic Council member of the All-Party Parliamentary Group (APPG) on Obesity, the Honorary Treasurer for the Association for Study of Obesity (ASO), and a Member of Obesity Policy Engagement Network UK (OPEN UK). It was agreed that these interests would not prevent Patrick McGinley from participating in the meeting.

The following specialist committee members had notified these interests in advance of the meeting:

Sotirios Bisdas declared financial interests due to private practice privileges at Queen Square Private Imaging Centre, HCA Chiswick, UCH and Portland Hospitals. He has been a member of the Advisory Board and has received consultancy fees from Image Analysis Group, London/UK – Philadelphia/USA. He undertakes private medicolegal work. He has share options and received benefits in kind for speaking engagements from Advantis Medical, Amsterdam/NL. He has been a Member of the Advisory Board and received benefits in kind and payment for speaking engagements and consultancy, respectively: Olea Medical, La Ciotat/France. He is co-founder of the company Medicon.AI Ltd.

He also declared non-financial professional and personal interests as he is a Member of the AI committee of the British Society of Neuroradiologists (BSNR); Clinical Lead of the AI Committee, Department of Neuroradiology, The National Hospital for Neurology and Neurosurgery, UCL Hospitals NHS Trust; Principal Investigator in a submitted funding application for the NIHR AI programme Stage 3 about AI-assisted MRI and CT for tumours and stroke diagnosis; Secretary and Professional Relationships Liaison for the European Society of Medical Imaging and Informatics; and eHealth and Informatics Subcommittee Member, European Society of Radiology.

He also declared indirect interests as he is the Associate Editor of the AI section in the journal Cancer Imaging, Springer; and he is co-founder of the NPO “Society of Advanced Neuroimaging”, Athens/Greece. He is a friend of the co-founder and CTO of the Medicon.AI Ltd. He has been appointed by the European Society of Medical Imaging and Informatics to represent it in the American Society of Imaging Informatics.

It was agreed that these interests would not prevent Sotirios Bisdas from participating in the meeting.

Margaret Cheng declared non-financial personal and professional interests as she is a Trustee of the Research Institute for Disabled Consumers; a member of the PPI group for the ReTaKE (Return to Work after Stroke) project run by Nottingham University; an expert panel member (PPI) for the HEE Pre-Doctoral Bridging Programme at Nottingham University; lay member of the NICE committee reviewing the guideline for rapid blood pressure reduction following intracerebral haemorrhage; and a public representative on the HSDR programme funding committee (NIHR). It was agreed that these interests would not prevent Margaret Cheng from participating in the meeting.

Tim England declared indirect interests as his head of department (Stroke, University of Nottingham) is undertaking research with Brainomix, including the use of CT scans from the RIGHT-2 trial and the Real-world Independent Testing of e-ASPECTS Software (RITeS) study. His employer, the University of Nottingham, has received a research grants from the NIHR to conduct the RECAST-3 trial (grant number NIHR128240) and the TICH-3 trial (grant number NIHR 29917). It was agreed that these interests would not prevent Tim England from participating in the meeting.

Carole Gavin declared non-financial personal and professional interests as she is Vice President (Membership) Royal College of Emergency Medicine (RCEM) and may be involved in formulation of national policy, advice, clinical guidelines etc produced by RCEM. It was agreed that this interest would not prevent Carole Gavin from participating in the meeting.

Nigel Hoggard declared financial interests as he undertakes private practice. He declared indirect interests as he had been approached to act as a consultant neuroradiologist reporting research brain scans on behalf of GE Healthcare Limited, with remuneration to go to his university department; and he is an expert reviewer of study new contrast agent imaging for GE Healthcare (the study is on a new intravenous MR contrast agent, there is no CT component, and remuneration goes to University of Sheffield). He also declared a non-financial professional and personal interest as he is Professor of Neuroradiology, University of Sheffield. It was agreed that these interests would not prevent Nigel Hoggard from participating in the meeting.

Grant Mair declared a financial interest as had received consultancy fees from Canon Medical Research Europe (Ltd), to provide expert assessment of CT brain scans of patients with stroke. These data are intended for future development of artificial intelligence software (similar to those under consideration by the committee). All intellectual property relating to this project will remain with Canon and he has no financial gain beyond the initial consultancy fees.

He also declared non-financial personal and professional interests as he is Chief Investigator for the RITeS (Real-world Independent Testing of e-ASPECTS Software) study to assess AI software (from Brainomix Ltd.) used for CT assessment in stroke. RITeS was commissioned and is principally funded by the Stroke Association (10% contribution from the MRC) and all funding goes direct to his University. RITeS was planned and is conducted independent of and with no funding from Brainomix. RITeS will compare e-ASPECTS and e-CTA results with expert human interpretation of the same CT imaging and will assess users’ opinions. He has supervised an MSc student project to systematically review the evidence for AI software used to assess CT in stroke. He was invited by the Royal College of Radiologists (RCR) to write an opinion piece on AI in radiology for their newsletter. He was an invited speaker at the 2021 European Stroke Organisation Conference to talk on the evidence base for AI software in the diagnosis and acute treatment of stroke. He is leading a RITeS collaboration research funding proposal submitted following invitation from the Scottish Thrombectomy Advisory Group. The proposed research would provide independent comparative testing of up to 5 potential AI software packages designed for use with acute stroke imaging. Research would be funded by the Scottish Government direct to his University. He is the named collaborator on an NIHR grant application to clinically evaluate the implementation of StrokeViewer AI software (NICO.LAB) in his local NHS department, the research to be conducted independent of NICO.LAB with funding direct to his University. He is

involved in early steering group discussions to form a new AI panel for the British Society of Neuroradiologists.

He also declared an indirect interest as in 2021 he was invited by the RCR to co-host a mini webinar series exploring AI software for stroke radiology, his involvement with the event was non-financial. It was agreed that these interests would not prevent Grant Mair from participating in the meeting.

Kiruba Nagaratnam declared financial interests as he undertakes private practice, and has received speaker fees and educational grants from Boehringer Ingelheim. It was agreed that these interests would not prevent Kiruba Nagaratnam from participating in the meeting.

Jonathan Shapey declared financial interests as he is Co-Founder and Clinical Advisor to Hypervision Surgical Ltd. He also declared non-financial personal and professional interests as he is a Senior Clinical Lecturer, King’s College London; he has written an opinion/news article highlighting the value of artificial intelligence in the management of neurosurgery patients (https://doi.org/10.1016/j.wneu.2021.03.010); and he is a King’s MedTech Hub Board member. He also declared indirect interest as he is a KHP Board of Surgery Committee Member and is employed by King’s College London (employer benefits from associated research grants). It was agreed that these interests would not prevent Jonathan Shapey from participating in the meeting.

Li Su declared a non-financial professional and personal interest as he is Member of Alzheimer’s Society Research Strategy Council. It was agreed that this interest would not prevent Li Su from participating in the meeting.

David Werring declared a financial interest as he had received honoraria from Bayer 2016-2021 (talks and debates on anticoagulants and intracerebral haemorrhage, which were educational, and did not directly promote the use of any specific therapy). He also declared non-financial professional and personal interests as he is Honorary Secretary, British Association of Stroke Physicians and Chair, Stroke Advisory Group, Association of British Neurologists. It was agreed that these interests would not prevent David Werring from participating in the meeting.

The Committee proceeded to discuss the clinical effectiveness and cost effectiveness of ‘Software with artificial intelligence derived algorithms for analysing CT brain scans in people with a suspected acute stroke’.

* + 1. The Committee was asked if there were any specific equality issues to consider in relation to this assessment.
		2. The Chair asked the representatives of the manufacturers whether they wished to comment on any matters of factual accuracy.
		3. The Chair thanked the manufacturer representatives, the external assessment group representatives, and public observers for their attendance at the meeting.
		4. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.
	1. Part 2 - Closed session
		1. The committee then agreed on the content of the Diagnostics Consultation Document (DCD). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the DCD in line with their decisions.

### Date of the next meeting

The next meeting of the Diagnostics Advisory Committee (next topic) will be held on 22 March 2022.